A recent trial concerning the heartburn medication Zantac concluded with a hung jury, with jurors unable to determine if Boehringer Ingelheim should be held liable for damages claimed by an Illinois man who developed prostate cancer after taking the drug. This marks the second consecutive time a jury has failed to reach a verdict in similar litigation following the drug’s discontinuation amid cancer-related allegations. Plaintiff Ronald Kimbrow, who took Zantac for over two decades, had previously settled with other defendants in the case. The ongoing legal challenges stem from a 2020 FDA request to withdraw Zantac from the market due to concerns over a potentially carcinogenic byproduct.